Document Detail


Quantitative assessment of UVA-riboflavin corneal cross-linking using nonlinear optical microscopy.
MedLine Citation:
PMID:  21508101     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Corneal collagen cross-linking (CXL) by the use of riboflavin and ultraviolet-A light (UVA) is a promising and novel treatment for keratoconus and other ectatic disorders. Since CXL results in enhanced corneal stiffness, this study tested the hypothesis that CXL-induced stiffening would be proportional to the collagen autofluorescence intensity measured with nonlinear optical (NLO) microscopy.
METHODS: Rabbit eyes (n = 50) were separated into five groups including: (1) epithelium intact; (2) epithelium removed; (3) epithelium removed and soaked in riboflavin, (4) epithelium removed and soaked in riboflavin, with 15 minutes of UVA exposure; and (5) epithelium removed and soaked in riboflavin, with 30 minutes of UVA exposure. Corneal stiffness was quantified by measuring the force required to displace the cornea 500 μm. Corneas were then fixed in paraformaldehyde and sectioned, and the collagen autofluorescence over the 400- to 450-nm spectrum was recorded.
RESULTS: There was no significant difference in corneal stiffness among the three control groups. Corneal stiffness was significantly and dose dependently increased after UVA (P < 0.0005). Autofluorescence was detected only within the anterior stroma of the UVA-treated groups, with no significant difference in the depth of autofluorescence between different UVA exposure levels. The signal intensity was also significantly increased with longer UVA exposure (P < 0.001). Comparing corneal stiffness with autofluorescence intensity revealed a significant correlation between these values (R(2) = 0.654; P < 0.0001).
CONCLUSIONS: The results of this study indicate a significant correlation between corneal stiffening and the intensity of collagen autofluorescence after CXL. This finding suggests that the efficacy of CXL in patients could be monitored by assessing collagen autofluorescence.
Authors:
Dongyul Chai; Ronald N Gaster; Roberto Roizenblatt; Tibor Juhasz; Donald J Brown; James V Jester
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-06-16
Journal Detail:
Title:  Investigative ophthalmology & visual science     Volume:  52     ISSN:  1552-5783     ISO Abbreviation:  Invest. Ophthalmol. Vis. Sci.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-17     Completed Date:  2011-09-01     Revised Date:  2013-06-30    
Medline Journal Info:
Nlm Unique ID:  7703701     Medline TA:  Invest Ophthalmol Vis Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4231-8     Citation Subset:  IM    
Affiliation:
The Gavin Herbert Eye Institute, University of California, Irvine, Irvine, California 92697, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cornea / drug effects,  pathology*,  radiation effects
Cross-Linking Reagents
Disease Models, Animal
Keratoconus / metabolism,  pathology,  therapy*
Microscopy
Rabbits
Riboflavin / therapeutic use*
Ultraviolet Rays*
Ultraviolet Therapy / methods*
Vitamin B Complex / therapeutic use
Grant Support
ID/Acronym/Agency:
EY016663/EY/NEI NIH HHS; EY018665/EY/NEI NIH HHS; EY019719/EY/NEI NIH HHS; EY07348/EY/NEI NIH HHS; R01 EY019719/EY/NEI NIH HHS
Chemical
Reg. No./Substance:
0/Cross-Linking Reagents; 12001-76-2/Vitamin B Complex; 83-88-5/Riboflavin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Endogenic regulation of proliferation and zinc transporters by pigment epithelial cells nonvirally t...
Next Document:  Notch signaling modulates MUC16 biosynthesis in an in vitro model of human corneal and conjunctival ...